Beyond the Cage: How the FDA Modernization Act is Accelerating the Shift Toward Human-Based Models
The FDA Modernization Act 2.0 has opened the door to a new era in preclinical research — one powered by organoids, organs-on-chips, iPSC systems, ex vivo human tissues, and AI-driven prediction tools. As regulators push for human-relevant science, these technologies are reshaping how drugs are designed, tested, and brought to patients. This article explores how and why the shift is accelerating.
The Living Lab Bench: The Role of 3D Bioprinting in Smarter Drug Development
What if we could print living tissue—tiny hearts, slivers of brain, even organ systems—right in the lab? 3D bioprinting is revolutionizing drug development, personalized medicine, and regenerative therapies. Explore how this groundbreaking tech is reshaping the future of biology, one printed layer at a time.